1 Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, New Haven, CT.
2 Division of Vascular Neurology, Department of Neurology, Yale School of Medicine, New Haven, CT.
3 Neurovascular Surgery, Department of Neurosurgery, Yale School of Medicine, New Haven, CT.
4 Vascular Neurology, Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, IL.
5 Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC.
6 Department of Neurology, University of Cincinnati, Cincinnati, OH.
7 Division of Neurocritical Care, Department of Neurology, Weill Cornell Medicine, New York, NY.
8 Department of Neurology, University of Missouri, Columbia, MO.
9 Zeenat Qureshi Stroke Institute, St. Cloud, MO.
10 Department of Neurology, Henry Ford Hospital, Detroit, MI.
Ms. Leasure is supported by the National Institutes of Health (NIH) (R03NS112859). Dr. Sansing is supported by the NIH (R01NS095993, R01NS097728, U01NS113445). Dr. Kamel is supported by the NIH (R01NS097443, U01NS095869, R01HL144541, U01NS106513). Dr. Murthy is supported by the NIH (K23NS105948) and the Leon Levy Foundation. Dr. Sheth is supported by the NIH (U24NS107136, U24NS107215, R01NR018335, U01NS106513, R03NS112859) and the American Heart Association (18TPA34170180,17CSA33550004). Dr. Falcone is supported by the National Institute on Aging (K76AG59992), the National Institute of Neurological Disorders and Stroke (R03NS112859), the American Heart Association (18IDDG34280056), a Yale Pepper Scholar Award (P30AG021342), and the Neurocritical Care Society Research Fellowship. Drs. Acosta, Sansing, Langefeld, Woo, Sheth, and Falcone received support for article research from the NIH. Drs. Langefeld’s and Woo’s institutions received funding from the NIH. Dr. Kamel serves as a principal investigator for the NIH-funded AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA) trial (National Institute of Nuerological Disoders and Stroke U01NS095869), which receives in-kind study drug from the Bristol-Myers-Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics, serves as Deputy Editor for JAMA Neurology, serves as a steering committee member of Medtronic’s Stroke atrial fibrillation trial (uncompensated), serves on an end point adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim, and has served on an advisory board for Roivant Sciences related to Factor XI inhibition. Dr. Mayer recieved funding from Idorsia, MaxQ AI, Bayer, Brain Cool, Biogen, and Nestle. Dr. Sheth’s institution received funding from Biogen, Novartis, and Bard, and he recieved funding from Hyperfine and Zoll. The remaining authors have disclosed that they do not have any potential conflicts of interest.
The funding entities had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; or decision to submit the article for publication.
For information regarding this article, E-mail: [email protected]
